Half of Teens Drop Below Obesity Cutoff With Semaglutide

The STEP TEENS Results: A Closer Look at the Numbers

Doctor Mike Hansen goes deep on the STEP TEENS trial data in this video, and the headline finding is remarkable: approximately half of the adolescents treated with semaglutide dropped below the obesity cutoff during the study period. For a trial studying teenagers who started with clinically significant obesity, that is a result that would have been almost unthinkable a decade ago with lifestyle interventions alone.

Hansen walks through the trial design first. STEP TEENS enrolled adolescents aged 12-17 with a BMI at or above the 95th percentile for their age and sex (the standard clinical definition of obesity in children). All participants received lifestyle counseling alongside either semaglutide 2.4mg weekly (the same dose used in Wegovy for adults) or placebo. The study ran for 68 weeks, with the primary endpoint being the percentage change in BMI from baseline.

The results were clear. The semaglutide group experienced an average BMI reduction of about 16.1%, compared to a 0.6% increase in the placebo group. When you translate BMI changes into weight categories, roughly half of the semaglutide-treated teens moved from the obese category to overweight or normal weight. The placebo group, despite receiving the same lifestyle counseling, showed virtually no change. This stark difference demonstrates that for many adolescents with established obesity, lifestyle intervention alone is not enough, and the addition of pharmacotherapy can produce transformative results.

Why These Results Matter for Adolescent Health

Hansen makes an important point about why adolescent obesity is more than adult obesity in a younger body. Adolescence is a critical period for metabolic programming. The metabolic patterns established during teenage years tend to persist into adulthood. An adolescent who enters their twenties with severe obesity has already accumulated years of metabolic stress, including insulin resistance, chronic inflammation, and potentially early cardiovascular damage. Intervening during adolescence has the potential to redirect these trajectories before decades of damage accumulate.

He also discusses the cardiometabolic improvements observed in the trial beyond weight loss. Semaglutide-treated teens showed improvements in waist circumference, A1C, fasting insulin, triglycerides, and liver enzymes. These are the markers that track with long-term disease risk, and seeing them improve in teenagers who were previously on a trajectory toward early adult diabetes and cardiovascular disease is genuinely encouraging.

The mental health dimension gets attention too. While the STEP TEENS trial was not designed to measure mental health outcomes as primary endpoints, the investigators collected quality-of-life data that showed meaningful improvements in the treatment group. Hansen connects this to the broader research on adolescent obesity and mental health, noting that weight-related bullying, body dissatisfaction, and social isolation are pervasive in this population and that effective weight management often produces psychological benefits that extend well beyond the scale.

The Safety Picture in Growing Bodies

Hansen is responsible in his coverage of safety, dedicating a significant portion of the video to what we know and what we do not know. The side effects observed in STEP TEENS were consistent with adult trials: nausea, vomiting, and diarrhea were most common and generally decreased over time. There were no signals of growth suppression, bone density changes, or pubertal disruption during the trial period. This is reassuring but incomplete, because 68 weeks is a relatively short window for evaluating effects on development that unfold over years.

He specifically addresses the growth concern, which is the question most parents ask first. Adolescents are still growing in height, and any intervention that significantly reduces caloric intake raises theoretical concerns about growth velocity. The trial data showed that linear growth was not impaired in the semaglutide group, but Hansen correctly notes that this needs to be confirmed in longer-duration studies and in younger adolescents who have more growth remaining.

The question of bone health also comes up. Rapid weight loss in adults has been associated with reductions in bone mineral density, and this concern is amplified in adolescents who are still building peak bone mass. The STEP TEENS trial did not fullly assess bone density, which Hansen identifies as a gap that future studies should address. He recommends that any adolescent on GLP-1 therapy have baseline and follow-up bone density assessments, particularly if they are in the earlier stages of puberty when bone mineralization is most active.

What This Video Does Well and Where Viewers Should Supplement

Hansen's strength is making clinical trial data accessible without oversimplifying. He presents the numbers clearly, provides appropriate context, and is transparent about the limitations of the evidence. His emphasis on the developmental uniqueness of adolescence adds a dimension that many adult-focused GLP-1 commentators miss. The balance between enthusiasm for the results and caution about long-term unknowns is well-calibrated.

Where viewers might want to supplement is on the practical side. The video does not deeply address insurance coverage barriers, which are significant for pediatric GLP-1 prescriptions. It also does not discuss the specific criteria that pediatric providers use to decide which adolescents are appropriate candidates for medication versus those who should continue with lifestyle interventions. These are important practical questions for parents and families watching the video and wanting to know whether this applies to their child.

The responder analysis from STEP TEENS reveals important individual variation hidden by the average numbers. While the mean BMI reduction was about 16%, some adolescents achieved far more dramatic results (25-30% BMI reduction) while others responded modestly (5-10%). Understanding what predicts a strong versus modest response would allow better patient selection and expectation setting. Factors that may influence response include baseline BMI severity, genetic variants in GLP-1 receptor expression, pubertal stage, baseline insulin resistance level, and dietary composition. As more adolescent data becomes available, the field should move toward a more personalized approach to pediatric GLP-1 therapy rather than a one-size-fits-all prescribing model.

The placebo group's outcome in STEP TEENS is as informative as the treatment group's. Despite receiving the same intensive lifestyle counseling as the semaglutide group, placebo participants showed virtually no improvement in BMI over 68 weeks. This is not because the lifestyle counseling was bad. It reflects the biological reality that for adolescents with established obesity, the metabolic and neurological drivers of excess weight are powerful enough to override behavioral interventions in most cases. This finding provides strong evidence that pharmacotherapy fills a genuine therapeutic gap for this population, not because lifestyle changes do not matter (they do), but because they are insufficient alone for many patients.

The question of treatment duration in adolescents is more complex than in adults because the developmental timeline adds additional variables. An adult who starts semaglutide at age 45 might take it indefinitely. An adolescent who starts at age 14 faces the question of whether they should continue through puberty, into young adulthood, and potentially for decades. The cost, the commitment, and the unknown long-term effects all weigh differently when the time horizon is potentially 50+ years of treatment. Some experts advocate for using GLP-1 therapy during the critical adolescent period to establish a lower weight trajectory and then attempting a carefully managed discontinuation in early adulthood. Others argue that the biological drivers of obesity do not resolve with time and that ongoing treatment is likely necessary regardless of when it was initiated. This debate remains unresolved and is one of the most important questions in pediatric obesity medicine.

Questions for Your Child's Healthcare Team

If you are considering GLP-1 therapy for your adolescent, these are the questions to work through. Does my child meet the specific clinical criteria for pharmacotherapy (BMI percentile, comorbidities, prior intervention history)? Which provider should manage this treatment: our pediatrician, a pediatric endocrinologist, or an adolescent medicine specialist? What monitoring schedule is recommended for growth, bone health, and metabolic markers? How do we handle the school and social aspects of weekly injections? What is the plan for transitioning care if medication continues into adulthood? And what dietary and exercise support should be in place alongside the medication?

The impact on weight-related comorbidities in the STEP TEENS trial extends the clinical significance beyond BMI numbers. Several participants with elevated fasting glucose saw their numbers normalize. Participants with elevated liver enzymes, a marker of fatty liver disease, showed meaningful improvements. Those with early signs of cardiovascular risk, including elevated blood pressure and dyslipidemia, also improved. These comorbidity improvements are especially significant in the adolescent population because they represent the prevention of disease progression rather than the treatment of established disease. Preventing a teenager from developing type 2 diabetes is qualitatively different from treating a 50-year-old who has had diabetes for 20 years. The earlier the intervention, the more disease trajectory you can redirect, which is the fundamental argument for not waiting until adulthood to treat significant adolescent obesity pharmacologically.

Hansen also briefly discusses the ethical framework around clinical trial enrollment for adolescents, which raises different considerations than adult trials. Adolescents cannot provide fully independent informed consent; they provide assent while their parents provide consent. The risk-benefit calculus is evaluated differently for minors than for adults, with regulatory agencies applying stricter scrutiny to pediatric trials. The STEP TEENS trial went through additional ethical review processes beyond what adult obesity trials require, and the safety monitoring was more intensive. Understanding this context is reassuring for parents who may worry that adolescent trial data is somehow less rigorous than adult data. If anything, the opposite is true: the regulatory bar for demonstrating safety and efficacy in adolescents is higher than for adults, which means that data meeting that bar carries additional credibility.

Who Should Watch This

Parents and guardians of adolescents with obesity should watch this for the clinical data alone. The STEP TEENS results are some of the most important data in pediatric obesity medicine, and Hansen presents them accessibly. Pediatricians and family medicine providers who are seeing increasing requests for GLP-1 prescriptions in their adolescent patients will benefit from the detailed trial review. Adolescent patients themselves, if they are old enough to engage with health information at this level, might find it empowering to understand the science behind a treatment that affects their daily life. And anyone with a general interest in GLP-1 medications will find the pediatric data an interesting extension of what they already know about these drugs in adults.